The Next Era of Gene Editing Will Be Disease Agnostic

At the wire Health Summit Last week, Harvard Biochemist and gene-editing Agrani David Liu said that later this year his lab planned to report on a single gene-editing technique that could treat many related diseases. He called it an editor of disease-non-non-nonsense therapeutic gene.

“It sounds crazy, but there is a very good molecular biology that may be possible,” he said stopped details on Boston’s audience.

Gene-editing treatment is currently being created for a number of rare and inherited genetic diseases. A gene-editing treatment, called CassiviCommercially allowed and available for the treatment of a related blood disorder called Sikel Cell Disease and Beta Thalassemia. Earlier this year, a baby boy named Kage Muldun was often born with deadly genetic disease that made ammonia in his blood, saved with one Customized gene-editing treatmentFirst a medical in the first.

These treatments work on specific mutations related to those diseases. However, they can be expensive to develop and must be designed for a specific patient population. Sometimes the population of that patient may be very small, such as in the case of baby KJ. Its condition, which is called CPS 1 deficiency, affects only one in the 1.3 million live birth.

Liu imagines a future where they can be used in a gene-editing procedure in multiple different diseases regardless of the organs or tissues that they affect or their genetic causes. He says that this type of flowing technique is needed because collectively, there are many rare diseases and it will be unreasonable to design treatment for everyone. Global genes, a rare disease advocacy company, assumes that there are at least 10,000 rare diseases that affect more than 400 million people worldwide.

Photograph: Vail Fuchi

“Overall genetic disease is not so rare as it is, it is actually many times more common than cancer or HIV/AIDS,” Liu said. “The root causes of these genetic diseases need these ways urgently to treat direct treatment.”